Trial Profile
A Placebo-controlled, Double-blind, Randomised, Parallel-group, Long Term Phase III Trial Assessing the Safety and Efficacy of Eprotirome in Patients With Heterozygous Familial Hypercholesterolaemia Who Are on Optimal Standard of Care.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 02 Aug 2022
Price :
$35
*
At a glance
- Drugs Eprotirome (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Acronyms AKKA
- Sponsors Karo Bio
- 31 Jul 2022 This trial has been completed in Denmark, according to European Clinical Trials Database record.
- 30 Mar 2014 Results presented at the 63rd Annual Scientific Session of the American College of Cardiology.
- 09 May 2012 Additional lead trial investigator (Santosh Jamboti) identified as reported by Clinical Trials Registry - India.